Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
BioPharma Dive14h
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on ...
PharmiWeb22h
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
FDA approves new pain drug Journavx as opioid alternative
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
Vertex: Risky Valuation Amid Shaky Organic Growth
Vertex specializes in corporate tax compliance software, targeting a $22B global TAM with a focus on enterprise and SMB ...
New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
FDA approves opiate-alternative acute pain management drug, local experts share their thoughts
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
C&EN12h
FDA approves new nonopioid pain medication, hailed a 'triumph'
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
Nasdaq5d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
Vertex has built an empire in cystic fibrosis ... Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription ...